SAFETY OF GANODERMA LUCIDUM EXTRACT

灵芝提取物的安全性

• 批准号: 7604792
• 负责人: CHUN-SU YUAN
• 金额: $ 2.7万
• 依托单位: UNIVERSITY OF CHICAGO
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-03-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7604792
• 关键词: Adverse effects; Asians; Blood Tests; Clinical Research; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Condition; Country; Daily; Dose; Funding; Future; Grant; Herbal Medicine; Human Volunteers; Immunity; Institution; Intake; Laboratories; Medical; Numbers; Oral; Personal Satisfaction; Placebos; Questionnaires; Reishi mushroom; Research; Research Personnel; Resistance; Resources; Safety; Source; Test Result; Testing; United States National Institutes of Health; day; human subject

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Ganoderma lucidum is an herbal medicine commonly used in oriental countries as a remedy for treating various medical conditions. In this clinical study, we tested the safety of oral intake of Ganoderma lucidum in 16 human volunteers. The human subjects received 2 grams of the herbal extract or placebo twice daily for 10 consecutive days. During the study, information from subjective questionnaires indicating their well-being were obtained, and several different laboratory tested were performed. In addition, blood tests reflecting immunity or body resistance to certain illness were done. Our study results showed that compared to placebo group, no adverse effects were observed after the herbal extract intake. Due to relatively small number of subject participated in this study, the immunity test results were not conclusive, and thus, remains to be re-evaluated in the future. Our study also suggested that an additional long-term safety clinical trial with higher herbal dose is needed.

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 灵芝是东方国家常用的一种草药，用于治疗各种疾病。在这项临床研究中，我们测试了16名志愿者口服灵芝的安全性。人类受试者连续10天每天两次服用2克草本提取物或安慰剂。在研究期间，从主观问卷中获得了表明他们幸福的信息，并进行了几种不同的实验室测试。此外，还进行了血液测试，以反映对某些疾病的免疫力或身体抵抗力。我们的研究结果表明，与安慰剂组相比，服用草药提取物后没有观察到不良反应。由于参与本次研究的受试者数量相对较少，免疫力测试结果并不是决定性的，因此，有待于以后的重新评估。我们的研究还表明，需要进行额外的长期安全性临床试验，并增加草药剂量。